CA-ESRI
A new app that can manage conservation plans and verify corporate environmental promises with clear imagery from the sky is being powered in partnership with Esri and its ArcGIS Image for ArcGIS Online. The Ranger app from Skytec, a Chattanooga, Tennessee-based geospatial and remote sensing firm, uses aerial drones and satellite imagery to remotely monitor a subscriber's property from above.
Ranger provides notifications when changes emerge, without the costly expense and time spent for on-site monitoring. Observable changes to the land could include encroachment by others; deforestation; impending pest infestations; and other environmental concerns including natural and unnatural disasters such as floods, fires, and spills.
"ArcGIS Image for ArcGIS Online has given us more time to focus on what we do best—analysis—rather than having to stand up the infrastructure operating behind the scenes. With Esri, those secure back-end systems are built in," said Skytec Chief Technology Officer Andrew Carroll.
The technology from Redlands, California-based Esri, the global leader in location intelligence, processes and securely stores the imagery powering Skytec's Ranger app in the cloud.
"Being able to understand and accurately measure success is half the battle in conservation, and this app allows users to know the precise impact of their efforts," said Jack Dangermond, Esri founder and president. "Skytec created the kind of sustainable solution our world needs to solve urgent climate concerns, and we're pleased to partner in providing the tools to help the firm grow."
Through Ranger, customers can choose how frequently they receive timed reports showing activity and highlighting changes on the areas they want monitored. If customers want more information about a change event, they can order higher-resolution satellite or drone imagery captured with lidar or send their own staff to observe in person. Those choices are then coordinated through Esri's ArcGIS Survey123 application.
Ranger is already monitoring more than 100,000 acres across the country with help from ArcGIS Image for ArcGIS Online. Among its clients are the Palmer Land Conservancy and the Hudson Highlands Land Trust.
Skytec CEO Bill Rogers and Carroll started the company as commercial drone operations began to take off, by monitoring small sites with unmanned aerial vehicles before expanding to include piloted flight observations. Now, with satellite imagery from Planet, Skytec wants Ranger to be a global solution to climate change by providing macro views of land showing if conservation strategies are working.
"We're anticipating clients' needs for seamless monitoring at any level of any location around the globe," Rogers said. "This service is beneficial for clients in a variety of industries, from natural resource management to environmental mitigation firms and utilities."
The application also has the potential to prove an entity has kept its environmental promises.
"There's an opportunity to begin to come in and fill the data science needs that are behind corporate sustainability initiatives," Carroll said. Monitoring can show where mitigation measures have been made, where growth has occurred, and what, if any, recovery has been achieved. It can also monitor for carbon offsets and ecological ecosystem banking.
"Everyone's talking a great talk, but where's the data behind it," Carroll said of what Ranger provides.
The Ranger application, built with Esri's ArcGIS Web AppBuilder, is optimized for desktop and tablet use. The partnership with Esri also gives Skytec and its Ranger customers access to the mapping leader's extensive library of online data, including its ArcGIS Living Atlas of the World, and a seamless experience for existing Esri users.
To learn how Esri can help businesses more easily access, process, and manage imagery in the cloud, visit go.esri.com/arcgisimage .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
